Managing oncology costs

American Journal of Managed Care

Volumn 12, Issue SUPPL. 1, 2006, Pages

  Reeder, Claiborne E ^a   Gordon, Debra ^b  

^a UNIVERSITY OF SOUTH CAROLINA COLLEGE OF PHARMACY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; LETROZOLE; NAVELBINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PEMETREXED; RECOMBINANT ERYTHROPOIETIN; TAMOXIFEN;

BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; LAW; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; ONCOLOGY; PATIENT ATTITUDE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; REVIEW;

COST CONTROL; COST OF ILLNESS; HEALTH CARE COSTS; HUMANS; MANAGED CARE PROGRAMS; MEDICAL ONCOLOGY; MEDICARE; MODELS, ECONOMIC; NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 33244458272     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. American Cancer Society. United States cancer statistics, 2002. Incidence and mortality. Available at: http://www.cdc.gov/cancer/npcr/uscs/index.htm. Accessed January 11, 2006.
2. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97:1407-1427.
3. Cancer Trends Progress Report-2005 Update. Available at: http://progressreport.cancer.go. Accessed January 5, 2006.
4. Medicare Payment Advisory Commission. Report to the Congress: Medicare payment policy. Washington, DC: MedPAC; March 2001.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
6. Schrag D. The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med. 2004;351:317-319.
7. Marcus AD. Price becomes factor in cancer treatment. Wall Street Journal. September 7, 2004:01, 07.
8. Appleby C. Payers' costly battle against cancer. Biotechnology Healthcare. 2005;19-25.
9. MCOs' oncology strategies focus on provider issues for 2005. Specialty Pharmacy News. 2005;2:1-3.
10. Congialose CB, Blair, AE, Borchardt JS, et al. Purchasing oncology services. Cancer. 2000;88:2876-2886.
11. Nadler ES, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Abstract presented at: American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 6011.
12. Kozma CM, Reeder CE, Schulz RM. Economic, clinical, and humanistic outcomes: a planning model for pharmacoeconomic research. Clin Ther. 1993;15:1121-1132.
13. Reeder CE, Kozma CM, McCollam AR. Overview of pharmaceutical outcomes, pharmacoeconomics, and quality of life. In: Ito SM, Blackburn SA, eds. Principles and Practices of Managed Care Pharmacy. Alexandria, Va: Academy of Managed Care Pharmacy; 1995:103-112.
14. Smith C, Cowan C, Heffler S, Catlin A. National health spending in 2004: recent slowdown led by prescription drug spending. Health Aff. 2006;25:186-196.
15. Centers for Medicare & Medicaid Services, Office of the Actuary, National Health Statistics Group. National Health Expenditures. http://www.cms.hhs.gov/NationalHealthExpendData/02_NationalHealthAccounts Historical.asp#TopOfPage. Accessed February 2, 2006.
16. Johnson N, Nash DB. Outcomes for P&T committees: where are we going? P&T. 1993:449-455.
17. Bennett CL, Lee T. Economic analysis of cancer treatment. In: Abeloff M, Armitage J, Niederhuber J, Kasta M, McKenna WG, eds. Clinical Oncology, 3rd ed. Edinburgh, UK: Churchill Livingstone; 2004:395-401.
18. Tengs TO. Cost effectiveness versus cost-utility analysis of interventions for cancer: does adjusting for health-related quality of life really matter? Value Health. 2004;7:70-78.
19. Schulman KA, Yabroff KR. Measuring the cost-effectiveness of cancer care. Oncology (Williston Park). 1995;9:523-530,533; discussion 533-528.
20. Berkowitz N, Gupta S, Silberman G. Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value Health. 2000;3:23-30.
21. Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer 1999 to 2000. J Clin Oncol. 2004;22:3524-3530.
22. Luce BR, Elixhauser A. Standards for the Socioeconomic Evaluation of Health Care Services. New York, NY: Springer-Verlag; 1990:57-60.
23. Calhoun EA, Chang CH, Welshman EE, Fishman DA, Lurain JR, Bennett CL. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist. 2001;6:441-445.
24. Turini M, Redaelli A, Gramegna P, Radice D. Quality of life and economic considerations in the management of prostate cancer. Pharmacoeconomics. 2003;21:527-541.
25. Radice D, Redaelli A. Breast cancer management: quality-of-life and cost considerations. Pharmacoeconomics. 2003;21:383-396.
26. Brown MM. Health care economic analyses. Curr Opin Ophthalmol. 2003;21:527-541.
27. Detmar SB, Muller MJ, Schornagel JH, Wever LD, Aaronson NK. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA. 2002;288:3027-3034.
28. Drummond MF, O'Brian B, Stoddart GL, et al. Methods for the Economic Evaluation of Healthcare Programmes. 2nd ed. New York, NY: Oxford University Press; 1997.
29. Ortega A, Dranitsaris G, Sturgeon J, Sutherland H, Oza A. Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Gynecol Oncol. 1997;66:454-463.
30. Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N. Rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small cell lung cancer. Health Technol Assess. 2001;5:1-195.
31. Cantor SB, Fahs MC, Mandelblatt JS, Myers ER, Sanders GD. Decision science and cervical cancer. Cancer. 2003;98:2003-2008.
32. Parmigiani G. Measuring uncertainty in complex decision analysis models. Stat Methods Med Res. 2002;11:513-537.
33. Secic M, Lang T. How to Report Statistics in Medicine: Annotated Guidelines for Authors, Editors and Reviewers. Philadelphia, Pa: American College of Physicians; 1997.
34. Lee JH, Glick HA, Hayman JA, Solin LJ. Decision-analytic model and cost-effectiveness evaluation of post-mastectomy radiation therapy in high-risk premenopausal breast cancer patients. J Clin Oncol. 2002;20:2713-2725.
35. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9:37-48.
36. Kaiser Family Foundation and Health Research and Educational Trust. Employer Health Benefits: 2005 Summary of Findings: Menlo Park, Calif; 2005.
37. Kaiser Family Foundation and Health Research and Educational Trust. Employer Health Benefits, 2004 Annual Survey Exhibit 7.1. September 2004. Available at: http://www.kff.org/insurance/7148/index.cfm. Accessed January 30, 2006.
38. McGivney WT, Mullen J. Cancer and managed care in the 21st century. Am J Manag Care. 2005;11(suppl 17):S509-S521.
39. Fuhrmans V. More employers try limited health plans. Wall Street Journal. January 17, 2006:D1.
40. Kaa K, Haenni B, Lopez T. Balancing payer policies with oncology practice management. Hematology Oncology News & Issues. 2002:12-13, 16-17, 34.
41. Centers for Medicare & Medicaid Services. CMS Legislative Summary. April 2004 Summary of H.R.1 Medicare Prescription Drug, Improvement, and Modernization Act of 2003; Public Law 108-173. Available at: http://www.cms.nhs.gov/MMAUpdate/downloads/PL108-173Summary.pdf. Accessed February 2, 2006.
42. Holcombe DG. Is oncology compatible with specialty pharmacy? Community Oncology. 2005;2:173-181.
43. Schwartz MH, Tartter PI. Decreased length of stay for patients with colorectal cancer: implications of DRC use. J Healthc Qual. 1998;20:22-25.
44. Kurowski B. Cancer carve outs, specialty networks, and disease management: a review of their evolution, effectiveness, and prognosis. Am J Manag Care. 1998;5:SP71-SP89.
45. Hassett MJ, Pakes J, O'Malley AJ, Newhouse JP, Earle CC. Chemotherapy-related serious adverse events and health care expenditures among commercially insured women with breast cancer. Presented at: American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla.
46. Pavlakis N, Mitchell PL, Stynes G, et al. Cost-effectiveness of pemetrexed for previously treated advanced non-small cell lung cancer. Presented at: American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla.
47. Cosler LE, Eldar-Lissai DC, Dale J, Crawford G, Lyman H. Economic analysis of pegfilgrastim in patients receiving cancer chemotherapy. Abstract presented at: American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 60410.
48. Ben-Hamadi R, Duh MS, Henckler A, McKenzie S, Fastenau J, Tak Piech C. Cost-effectiveness of once weekly epoetin alfa and darbepoetin alfa in treating chemotherapy-induced anemia. Abstract presented at: American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 6093.
49. Younis T, Skedgel C, Sellon M, et al. Economic evaluation of two adjuvant chemotherapy regimens in lung cancer: vinorelbine and cisplatin versus paclitaxel and carboplatin. Abstract presented at: American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 6076.
50. American Society of Clinical Oncology. Clinical Guidelines. Available at: http://www.asco.org/ac/1,1003,_12-002009,00.asp. Accessed January 24, 2006.
51. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Available at: http://www.nccn.org/professionals/ physican_gls/default.asp. Accessed January 24, 2006.